The partnership will run out of GlaxoSmithKline’s artificial intelligence hub in London. The drugmaker aims to use its clinical and genomic data in combination with Nvidia’s computing systems and Cambridge-1 supercomputer to drive breakthroughs for vaccine and drug discovery.
“We’re building new algorithms and approaches in addition to bringing together the best minds at the intersection of medicine, genetics and artificial intelligence in the U.K.’s rich ecosystem,” Kim Branson, PhD, GlaxoSmithKline’s senior vice president and global head of AI and machine learning, said in a news release. “This new partnership with NVIDIA will also contribute additional computational power and state-of-the-art AI technology.”
More articles on pharmacy:
Insulin in US costs up to 10 times more than in other wealthy countries, study says
Eli Lilly submits emergency authorization request for its COVID-19 antibody drug
Former vaccine official resigns from HHS months after demotion, whistleblower complaint
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.